Lymphoma News

The FDA approved omidubicel-onlv, a donor cord blood-based cell therapy, to accelerate neutrophil recovery and reduce the risk for infection among patients with hematologic malignancies undergoing stem cell transplantation.

Cardiovascular disease, especially atherosclerotic CVD, was associated with increased risk for cancer diagnosis, according to a study published in JACC: CardioOncology.

Results of a large meta-analysis indicated that Black race was associated with greater odds of cardiotoxicity and HF diagnosis after chemotherapy compared with white and non-Black race, a speaker reported.

Physicians recommended chimeric antigen receptor T-cell therapy more frequently than any other regimen for third-line treatment of relapsed or refractory diffuse large B-cell lymphoma, survey results showed.

Delirium appeared associated with higher ICU and hospital mortality, as well as increased length of stay, among critically ill patients with cancer, according to data published in JCO Oncology Practice.

Janssen and Pharmacyclics intend to voluntarily withdraw the U.S. indications of ibrutinib for certain patients with lymphoma, according to a press release.

A multi-institutional research project has demonstrated the superior value of whole-genome sequencing vs. exome sequencing in providing information about classic Hodgkin lymphoma.

Patients with hematologic malignancies reported significant improvement in quality of life after receiving chimeric antigen receptor T cells, results from a longitudinal study in Blood Advances showed.

University of Chicago Medicine Comprehensive Cancer Center has joined the National Comprehensive Cancer Network as its 33rd member institution.

HHS on Monday released the National Cancer Plan, which includes eight goals and strategies to prevent cancer, reduce related mortality and improve the lives of people living with the disease.